Activation of FKHRL1 plays an important role in protecting erythroid cells from erythropoietin deprivation-induced apoptosis in a human erythropoietin-dependent leukemia cell line, UT-7/EPO. 2007

Mie Uchida, and Keita Kirito, and Hitoshi Endo, and Keiya Ozawa, and Norio Komatsu
Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.

FKHRL1 is one of the human homologues of DAF-16, which is concerned with longevity in Caenorhabditis elegans. Previously, we demonstrated that FKHRL1 functions downstream of Akt in erythropoietin (EPO) signaling and that it is directly phosphorylated by activated Akt. Because phosphorylated FKHRL1 loses its transcriptional activity and translocates into the cytoplasm, FKHRL1 appears to be nonfunctional in the presence of EPO. Conversely, EPO deprivation leads to FKHRL1 dephosphorylation and its translocation into the nucleus, suggesting that FKHRL1 becomes active as a transcription factor in the absence of EPO. On the basis of these findings, we hypothesized, by analogy with C elegans, that erythroid cells possess self-defense machinery against life-threatening surroundings. We prepared a dominant-negative mutant of FKHRL1 (FKHRL1-DN) lacking the transactivation domain and prepared FKHRL1 small interfering RNA (siRNA), and we used constructs to transfect a human EPO-dependent cell line, UT-7/EPO. In the parental cells, 24-hour EPO deprivation induced transient cell cycle arrest without apoptosis. On the other hand, stable transfectants expressing FKHRL1-DN or FKHRL1 siRNA underwent rapid apoptosis after EPO deprivation in the UT-7/EPO cells. In conclusion, FKHRL1 activation plays an important role in the extension of survival of erythroid cells after EPO deprivation. This phenomenon appears to correspond to dauer formation in C elegans. Thus, the mechanism of lifespan extension may be broadly conserved from C elegans to humans.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002467 Cell Nucleus Within a eukaryotic cell, a membrane-limited body which contains chromosomes and one or more nucleoli (CELL NUCLEOLUS). The nuclear membrane consists of a double unit-type membrane which is perforated by a number of pores; the outermost membrane is continuous with the ENDOPLASMIC RETICULUM. A cell may contain more than one nucleus. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) Cell Nuclei,Nuclei, Cell,Nucleus, Cell
D003593 Cytoplasm The part of a cell that contains the CYTOSOL and small structures excluding the CELL NUCLEUS; MITOCHONDRIA; and large VACUOLES. (Glick, Glossary of Biochemistry and Molecular Biology, 1990) Protoplasm,Cytoplasms,Protoplasms
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071316 Forkhead Box Protein O3 A forkhead box transcription factor and transcriptional activator which triggers type 1 programmed cell death (APOPTOSIS) in the absence of APOPTOSIS INHIBITING PROTEINS, including neuronal cell death induced by OXIDATIVE STRESS. It recognizes and binds to the DNA sequence 5'-(AG)TAAA(TC)A-3' and also functions in post-transcriptional regulation of the c-MYC PROTO-ONCOGENE. FOXO3 Protein,Forkhead in Rhabdomyosarcoma-Like 1 Protein,Forkhead in Rhabdomyosarcoma Like 1 Protein,Protein, FOXO3
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D051858 Forkhead Transcription Factors A subclass of winged helix DNA-binding proteins that share homology with their founding member fork head protein, Drosophila. Forkhead Box Protein,Forkhead Box Transcription Factor,Forkhead Protein,Forkhead Transcription Factor,Forkhead Box Proteins,Forkhead Box Transcription Factors,Forkhead Proteins,Fox Transcription Factors,Box Protein, Forkhead,Box Proteins, Forkhead,Factor, Forkhead Transcription,Protein, Forkhead,Protein, Forkhead Box,Proteins, Forkhead Box,Transcription Factor, Forkhead,Transcription Factors, Forkhead,Transcription Factors, Fox

Related Publications

Mie Uchida, and Keita Kirito, and Hitoshi Endo, and Keiya Ozawa, and Norio Komatsu
July 1993, Blood,
Mie Uchida, and Keita Kirito, and Hitoshi Endo, and Keiya Ozawa, and Norio Komatsu
April 1994, Annals of the New York Academy of Sciences,
Mie Uchida, and Keita Kirito, and Hitoshi Endo, and Keiya Ozawa, and Norio Komatsu
March 2000, Experimental hematology,
Mie Uchida, and Keita Kirito, and Hitoshi Endo, and Keiya Ozawa, and Norio Komatsu
May 2015, Experimental hematology,
Mie Uchida, and Keita Kirito, and Hitoshi Endo, and Keiya Ozawa, and Norio Komatsu
July 1992, Blood,
Mie Uchida, and Keita Kirito, and Hitoshi Endo, and Keiya Ozawa, and Norio Komatsu
January 1998, Acta haematologica,
Mie Uchida, and Keita Kirito, and Hitoshi Endo, and Keiya Ozawa, and Norio Komatsu
May 2010, Clinical and experimental pharmacology & physiology,
Mie Uchida, and Keita Kirito, and Hitoshi Endo, and Keiya Ozawa, and Norio Komatsu
January 2000, Stem cells (Dayton, Ohio),
Mie Uchida, and Keita Kirito, and Hitoshi Endo, and Keiya Ozawa, and Norio Komatsu
May 1993, Experimental hematology,
Mie Uchida, and Keita Kirito, and Hitoshi Endo, and Keiya Ozawa, and Norio Komatsu
June 2005, Cancer science,
Copied contents to your clipboard!